Perioperative administration of propranolol to women undergoing ovarian cancer surgery: A pilot study.

ABSTRACT:

Objective

This study was done to evaluate whether perioperative propranolol (ß-blocker) in ovarian cancer patients undergoing debulking surgery reduced perioperative tumor growth induced by surgical stress.

Methods

This was a prospective randomized single institution analysis. The primary objective was to compare the changes in CA 125 level (changes between preoperation day 2 and postoperative day 7). As a study arm, patients received a low dose of propranolol 40 mg/day (4×10 mg) starting two days before surgery and 40 mg twice daily for three days following surgery.

Results

Twenty-two patients were enrolled and 16 were evaluable for efficacy. The drug was well tolerated. The mean decrease of CA 125 during the seven perioperative days was 83.1±8.9% in the propranolol

SUBMITTER: Jang HI 

PROVIDER: S-EPMC5364099 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature